NBNina A. Bickell

Nina A. Bickell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nina A. Bickell has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Rebeca Franco

    Icahn School of Medicine at Mount Sinai, New York, NY

    12 shared publications
  • Jenny J. Lin

    Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA

    8 shared publications
  • Ann Scheck McAlearney

    Icahn School of Medicine at Mount Sinai, Metropolitan Hospital Center, New York; Bronx-Lebanon Hospital Center, Jacobi Medical Center, Bronx; Kings County Hospital Center, NYU Lutheran Medical Center, Brooklyn Hospital Center, Brooklyn; Elmhurst Hospital Center, Elmhurst; Queens Cancer Center, Jamaica, NY; Newark Beth Israel Medical Center, Newark, NJ; and The Ohio State University, Columbus, OH

    7 shared publications
  • Kezhen Fei

    Icahn School of Medicine at Mount Sinai, Metropolitan Hospital Center, New York; Bronx-Lebanon Hospital Center, Jacobi Medical Center, Bronx; Kings County Hospital Center, NYU Lutheran Medical Center, Brooklyn Hospital Center, Brooklyn; Elmhurst Hospital Center, Elmhurst; Queens Cancer Center, Jamaica, NY; Newark Beth Israel Medical Center, Newark, NJ; and The Ohio State University, Columbus, OH

    7 shared publications
  • Rebeca Franco

    Departments of Population Health Science and Policy, and Medicine

    6 shared publications
  • Cardinale B. Smith

    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

    5 shared publications

Latest Publications

  • Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions

    by Nina A. Bickell, Anthony L. Back, Kerin Adelson, Jason P. Gonsky, Natalia Egorova, Sofya Pintova, Jenny J. Lin, Peter Kozuch, Emilia Bagiella, Cardinale B. Smith

    PURPOSE:Patients with advanced cancer often have a poor understanding of cancer incurability, which correlates with more aggressive treatment near the end of life (EOL). We sought to determine whet...


  • Where you live can impact your cancer risk: a look at multiple myeloma in New York City

    by Geetanjali R. Kamath, Anne S. Renteria, Sundar Jagannath, Emily Jane Gallagher, Samir Parekh, Nina A. Bickell


  • Open Access

    Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors

    by Geetanjali R. Kamath, Emanuela Taioli, Natalia N. Egorova, Josep M. Llovet, Ponni V. Perumalswami, Jeffrey J. Weiss, Myron Schwartz, Stanley Ewala, Nina A. Bickell

    Introduction: Liver cancer is the fastest increasing cancer in the United States and is one of the leading causes of cancer-related death in New York City (NYC), with wide disparities among neighborhoods. The purpose of this cross-sectional study was to describe liver cancer incidence by neighborhood and examine its association with risk factors. This information can inform preventive and treatment interventions. Materials and methods: Publicly available data were collected on adult NYC residents (n = 6,407,022). Age-adjusted data on liver and intrahepatic bile duct cancer came from the New York State Cancer Registry (1) (2007–2011 average annual incidence); and the NYC Vital Statistics Bureau (2015, mortality). Data on liver cancer risk factors (2012–2015) were sourced from the New York City Department of Health and Mental Hygiene: (1) Community Health Survey, (2) A1C registry, and (3) NYC Health Department Hepatitis surveillance data. They included prevalence of obesity, diabetes, diabetic control, alcohol-related hospitalizations or emergency department visits, hepatitis B and C rates, hepatitis B vaccine coverage, and injecting drug use. Results: Liver cancer incidence in NYC was strongly associated with neighborhood poverty after adjusting for race/ethnicity (β = 0.0217, p = 0.013); and with infection risk scores (β = 0.0389, 95% CI = 0.0088–0.069, p = 0.011), particularly in the poorest neighborhoods (β = 0.1207, 95% CI = 0.0147–0.2267, p = 0.026). Some neighborhoods with high hepatitis rates do not have a proportionate number of hepatitis prevention services. Conclusion: High liver cancer incidence is strongly associated with infection risk factors in NYC. There are gaps in hepatitis prevention services like syringe exchange and vaccination that should be addressed. The role of alcohol and metabolic risk factors on liver cancer in NYC warrants further study.


  • Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer

    by Nina A. Bickell, Natalia Egorova, Monica Prasad-Hayes, Rebeca Franco, Elizabeth A. Howell, Juan Wisnivesky, Partha Deb

    The best course of treatment for recurrent ovarian cancer is uncertain. We sought to determine whether secondary cytoreductive surgery for first recurrence of ovarian cancer improves overall survival compared with other treatments. We assessed survival using Surveillance, Epidemiology and End Results-Medicare data for advanced stage ovarian cancer cases diagnosed from January 1, 1997 to December 31, 2007 with survival data through 2010 using multinomial propensity weighted finite mixture survival regression models to distinguish true from misclassified recurrences. Of 35,995 women ages 66 years and older with ovarian cancer, 3439 underwent optimal primary debulking surgery with 6 cycles of chemotherapy; 2038 experienced a remission. One thousand six hundred thirty-five of 2038 (80%) women received treatment for recurrence of whom 72% were treated with chemotherapy only, 16% with surgery and chemotherapy and 12% received hospice care. Median survival of women treated with chemotherapy alone, surgery and chemotherapy, or hospice care was 4.1, 5.4, and 2.2 years, respectively (P<0.001). Of those receiving no secondary treatments, 75% were likely true nonrecurrences with median survival of 15.9 years and 25% misclassified with 2.4 years survival. Survival among women with recurrence was greater for those treated with surgery and chemotherapy compared with chemotherapy alone (hazard ratio=1.67; 95% confidence interval, 1.13-2.47). Women who were older with more comorbidities and high-grade cancer had worse survival. Secondary surgery with chemotherapy to treat recurrent ovarian cancer increases survival by 1.3 years compared with chemotherapy alone and pending ongoing randomized trial results, may be considered a standard of care.


  • Caution Ahead: Research Challenges of a Randomized Controlled Trial Implemented to Improve Breast Cancer Treatment at Safety-Net Hospitals

    by Nina A. Bickell, Ajay Shah, Maria Castaldi, Theophilus Lewis, Alan Sickles, Shalini Arora, Kevin Clarke, Margaret Kemeny, Anitha Srinivasan, Kezhen Fei, et al.

    To implement and test a Web-based tracking and feedback (T&F) tool to close referral loops and reduce adjuvant breast cancer treatment underuse in safety-net hospitals (SNHs). We randomly assigned 10 SNHs, identified patients with new stage 1 to stage 3 breast cancer, assessed their connection with the oncologist, and relayed this information to surgeons for follow-up. We interviewed key informants about the tool’s usefulness. We conducted intention-to-treat and pre- and poststudy analyses to assess the T&F tool and implementation effectiveness, respectively. Between the study start and intervention implementation, several hospitals reorganized care delivery and 49% of patients scheduled to undergo breast cancer surgery were ineligible because they already were in contact with an oncologist. One high-volume hospital closed. Despite randomization of hospitals, intervention (INT) hospitals had fewer white patients (5% v 16%; P = .0005), and more underuse (28% v 15%; P = .002) compared with usual care (UC) hospitals. Over time, INT hospitals with poorer follow-up significantly reduced underuse compared with UC hospitals (INT hospitals, from 33% to 9%, P = .001 v UC hospitals, from 15% to 11%, P = .5). There was no difference in underuse (9% at INT hospitals, 11% at UC hospitals; P = .8). Hospitals with better follow-up (odds ratio, 0.85; 95% CI, 0.73 to 0.98) had less underuse. In settings with poor follow-up and tracking approaches, key informants found the tool useful. The rapidly changing delivery landscape posed significant challenges to this implementation research. A T&F tool did not significantly reduce adjuvant underuse but may help reduce underuse in SNHs with poor follow-up capabilities. Inability to discern T&F effectiveness is likely due to encountered challenges that inform lessons for future implementation research.


  • Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers

    by Nina A. Bickell, Jenny J. Lin, Sarah R. Abramson, Gerald P. Hoke, William Oh, Simon J. Hall, Richard Stock, Kezhen Fei, Ann Scheck McAlearney

    Purpose: Black men are more likely to die as a result of prostate cancer than white men, despite effective treatments that improve survival for clinically significant prostate cancer. We undertook this study to identify gaps in prostate cancer care quality, racial disparities in care, and underlying reasons for poorer quality care. Methods: We identified all black men and random age-matched white men with Gleason scores ≥ 7 diagnosed between 2006 and 2013 at two urban hospitals to determine rates of treatment underuse. Underuse was defined as not receiving primary surgery, cryotherapy, or radiotherapy. We then interviewed treating physicians about the reasons for underuse. Results: Of 359 black and 282 white men, only 25 (4%) experienced treatment underuse, and 23 (92%) of these were black. Most (78%) cases of underuse were due to system failures, where treatment was recommended but not received; 38% of these men continued receiving care at the hospitals. All men with treatment underuse due to system failures were black. Conclusion: Treatment rates of prostate cancer are high. Yet, racial disparities in rates and causes of underuse remain. Only black men experienced system failures, a type of underuse amenable to health information technology–based solutions. Institutions are missing opportunities to use their health information technology capabilities to reduce disparities in cancer care.


  • Oncologists’ experiences with goals of care conversations.

    by Cardinale B. Smith, Rachel Solomon, Jenny J. Lin, Shelli Feder, Nina A. Bickell, Dena Schulman-Green

    50 Background: ASCO guidelines suggest that patients with advanced cancer should have goals of care (GoC) conversations with their oncologists, yet only 37% report having them, often at the end of life. Describing oncologists’ experiences with GoC conversations is a crucial first step in tailoring communication training interventions. Methods: We conducted semi-structured interviews with oncologists at academic, community, municipal, and rural hospitals (n = 4) in New York and Connecticut. We analyzed data using interpretive description. Three coders developed a code key, independently and then jointly coded transcripts, and identified themes. Results: Oncologists (n = 21) were 67% male, averaged 46 years old (range 34-68) and 20 years (range 8-42) in practice, and 59% reported training in GoC. Sixty-nine percent were White, 23% Asian, and 8% Hispanic. Within oncologist narratives we identified generalizable facilitators and detractors to their practice of GoC conversations. Facilitator experiences included formal training in GoC discussions, a practice culture that supported GoC conversations (i.e. presence of specialty level palliative care), interactions with patients who they perceived to have realistic expectations, and good strategies for self-care and coping. One oncologist stated, “I can't cry or die with every patient because then I won't make it through the day.” Detractors included patient failure to understand cancer severity or treatment goals, younger patient age, and being the oncologist sought for second opinion. Oncologists described active patient participation, respect for patient beliefs and values, and achieving agreement on a care plan as elements of successful GoC discussions. An oncologist summarized, “People who are in the healthcare field think that goals of care are an immutable statement, but it’s not.... the way you can make an effective goals of care discussion, is to relate to their reality.” Conclusions: Multiple considerations impact oncologists’ experiences with GoC conversations. Tailoring communication interventions to address these concerns may increase rates of earlier and ongoing GoC conversations. Clinical trial information: NCT02374255.

  • Does oncologist productivity impact goals of care discussions?

    by Sofya Pintova, Cardinale B. Smith, Kerin B. Adelson, Jason Parker Gonsky, Natalia Egorova, Rebeca Franco, Nina A. Bickell

    E21675 Background: Oncologists are pressed to care for higher volumes of advanced cancer patients. Interviews with oncologists revealed their concern that goals of care (GoC) discussions take time. We studied the impact of oncologists’ productivity on their conduct of meaningful GOC discussions with patients. Methods: At academic, municipal and rural hospitals, we recruited & randomized solid tumor oncologists & their newly diagnosed advanced cancer patients with

  • Thirty-day readmissions in metastatic cancer patients: Room for improvement?

    by Rachel Solomon, Natalia Egorova, Rebeca Franco, Nina A. Bickell

    6541 Background: To date, cancer has been excused from most readmission reduction efforts. Yet reported readmission rates for cancer patients discharged from medical services are as high as 27%. Some readmissions for patients with metastatic disease may be avoidable. We assessed the prevalence of potentially preventable readmissions and associated factors in adult patients with metastatic cancer. Methods: We measured 30 day readmissions for dehydration, cancer-related pain, and failure to thrive in patients with primary diagnosis metastatic cancer on index admission to a New York State hospital between December 1, 2012 and December 31, 2014. We used competing risk models to assess the effects of demographics, comorbidities, hospital type, payor, and discharge disposition. Results: During the study period, 11,275 patients had 19,307 index hospitalizations with primary diagnosis, metastatic cancer. The 30 day readmission rate was 24.5% of which 8.9% (424) were potentially preventable. Black (HR 1.26, 1.17-1.35) and Hispanic patients (HR 1.19, 1.09-1.31) had higher rates of readmission than whites. Being older (HR per 10 years of age 0.94, 0.90-0.97), female (HR 0.95, 0.91-0.99), having private insurance (HR 0.87, 0.87-0.81) and discharge to hospice (HR 0.62, 0.42-0.91) decreased risk of readmission. Discharge home with services (HR 1.21, 1.14-1.27) or to a skilled nursing facility (SNF) (HR 1.11, 1.01-1.23) conferred higher risk than going home unaided. Index hospitalization at public hospitals increased risk (HR 1.1, 1.02-1.18); teaching hospitals were protective (HR 0.84, 0.774-0.92). Patients with potentially preventable readmissions were younger (HR per 10 years of age 0.85, 0.78-0.93). Compared to those who went home unaided, patients discharged with services were more likely (HR 1.31, 1.05-1.64) and those discharged to SNF were less likely to have avoidable returns (HR 0.55, 0.37-0.81). Payor, gender, race, comorbidities, and index hospital type did not contribute. Conclusions: While the overall rate of potentially preventable admissions among metastatic cancer patients is low, higher readmission rates among those discharged home with help suggests that services supplied are not sufficient to address their health needs.


  • Does coaching goals of care discussion skills make a difference?

    by Nina A. Bickell, Kerin B. Adelson, Jason Parker Gonsky, Sofya Pintova, Benjamin Philip Levy, Jenny J. Lin, Rebeca Franco, Natalia Egorova, Cardinale B. Smith

    6586 Background: Advanced cancer patients often have a poor understanding of their cancer prognosis. Goals of Care (GoC) discussions provide information about the cancer, its treatment & prognosis and elicit patient values. Little is known about the best ways to enhance patient understanding, clarify values and move GoC discussions earlier in the disease process. We report the effect of coaching oncologists on GoC discussions. Methods: We recruited oncologists & their advanced cancer patients with < 2 year prognosis to a RCT testing a coaching model communication skills training. Patients were surveyed after their post-imaging visit. We define GoC discussions as patient report that their doctor talked about their cancer prognosis and clarified things most important to them given their disease. Outcome variables assess the impact of GoC on patients’ knowledge on what to expect and clarity of values. Results: We enrolled 22/25 (88%) oncologists and 70% of eligible patients of whom 96 (55%) completed a survey. On average, doctors were 44 yrs old (32-66) and in practice 14.5 yrs (5-40). Patients’ mean age was 62 yrs (20-95), 40% females, 58% white, 24% Latino & 22 % black. Overall, 2/3 of patients reported their treatment’s goal was to cure their cancer; 14% reported cure to be unlikely. Patients felt more knowledgeable (79% vs 21%; p = 0.02) when their doctors discussed treatments, side effects & quality of life. When patients were asked about things important to them, they report being a bit clearer about their values (65% vs 35%; p = 0.16). Compared to controls, intervention patients felt more knowledgeable (78% v 63%; p = 0.17) but did not feel clearer about their values (60% v 54%; p = 0.59). Multivariate modeling found that poor health literacy (OR = 0.2; 95%CI: 0.07-0.82), having a GoC discussion (OR = 10.2; 1.7-63.1) and being in the intervention group (OR = 8.8; 1.4-55.2) significantly affected knowledge (model c = 0.88; p < 0.01). However, discussing what’s important to patients did not help patients feel clearer about their values (OR = 2.7; 0.6-12.2; model c = 0.82; p < 0.05). Conclusions: Using a coaching model to teach oncologists communication skills may improve patients’ understanding of what to expect with their cancer but does not impact their clarity of values. Clinical trial information: NCT02374255.